Mustang Bio Gallops On Gene Therapy Trial Results For Bubble Boy Disease

Shares of Mustang Bio Inc. (MBIO) soared more than 349 percent to $11.96 in extended trading on Wednesday, following encouraging results of the company's MB-107, an investigational lentiviral gene therapy for the treatment of bubble boy disease.

from RTT - Biotech http://bit.ly/2KO1kGP
via IFTTT